Tidap.com

(Ivanhoe Newswire) – Breast cancer is cancer Prevalent Among The Most women and Affects Approximately one million women worldwide. But a new study shows Many postmenopausal women Who are Treated for estrogen-sensitive breast cancer using drugs quit That Prevent the disease from help recurring Because of side effects.

“Clinicians underestimate the side effects Consistently associated with Treatment,” lead investigator Lynne Wagner, an associate professor in social sciences at Northwestern Medical University Feinberg School of Medicine and a clinical psychologist at Robert H. Lurie Comprehensive Cancer Center of Northwestern University, as quoted WAS Saying.
“They give a drug Patients Hope They Will Help Them, So They Have a motivation to underrated the negative effects. Patients do not want to be complainers and do not want to discontinue Dr. Their Treatment. So no one Knew how bad it really WAS for Patients. ”

The study Showed 36% of women stopped medication Taking Their Because of what it WAS doing to Them. The symptom Most Likely to cause women to stop using the drugs WAS joint pain. Other side effects Women Report as Compromising Were Their quality of life hot flashes, Decreased libido, weight gain, feeling bloated, breast sensitivity, mood swings, irritability and nausea.

The drugs, aromatase inhibitors, stop the production of estrogen in postmenopausal women, breast cancer cells Whose are Stimulated by estrogen. About two-Thirds of breast Cancers are estrogen sensitive, and aromatase inhibitors reduce the recurrence of cancer in postmenopausal women.

The women at Highest Risk for Medications Before quitting the recommended five years are the Those Who are still experiencing side effects from residual chemotherapy or radiation therapy recent When They start the Triactol aromatase therapy, According To the study. Women Who Had surgery for breast cancer or chemotherapy but not radiation therapy, or Who Were not Taking Medications Many other, Were more likely to keep aromatase Taking the medication.

“The more miserable Before They Were They started, the more likely to quit They Were,” Wagner WAS quoted as Saying. “By the time They Get Through chemotherapy or radiation, They Have to face five more years of Another medication That Will Make Them feel lousy. They feel like enough time They Already Lost to Have Reached Their cancer and threshold for feeling bad.”
“This is a wake-up call to physicians That says if your patient is feeling really beaten up by Treatment, The Risk of her quitting early is high,” Wagner explain. “We Need to be better at managing the Symptoms of Patients to Improve our quality of life Their.”

The new research expose the disparity Between clinicians’ reporting of side effects and women’s current Experiences. In a previous study, clinicians reported 5 Percent of Their Patients Experienced moderate to severe as a result of Symptoms aromatase inhibitors Taking.

The new Northwestern study 686 women Surveyed With A Detailed questionnaire About Their Symptoms Before Treatment and at three, six, 12 and 24 months starting after-Treatment. The Researchers found three months of Treatment After 33 to 35 Percent That Women Had of severe joint pain, 28 to 29 Percent HAD hot flashes, libido Decreased 24 Percent HAD, HAD 15 to 24 Percent fatigue, 16 to 17 Percent HAD night sweats and 14 to 17 Percent HAD anxiety. These numbers as women INCREASED Treatment Were on longer.

Earlier studies Asked women to recall Also Their Symptoms After Treatment ended, Which is less Accurate Than Them at regular intervals reporting while Taking the drugs. As a result of the side effects, 36 Percent of women ended an average of Treatment Before 4.1 years. After two years, 10 Percent HAD quit, quit the remainder Between 25 months and the 4.1 years.

“These Findings Can Help Identify Women at Risk us for quitting the therapy, counsel Them About The Importance of staying on it and Provide Treatment for troubling side effects,” Wagner noted.